Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gestational trophoblastic tumors.

J R Lurain1

  • 1Section of Gynecologic Oncology, John I. Brewer Trophoblastic Disease Center, Northwestern University Medical School, Chicago, IL 60611.

Seminars in Surgical Oncology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participation of the general gynecologist in surgical staging of endometrial cancer: analysis of cost and perioperative outcomes.

Gynecologic oncology·2006
Same author

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2003
Same author

Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.

The oncologist·2001
Same author

Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer.

Gynecologic oncology·2001
Same author

Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.

Cancer investigation·1999
Same author

Oral contraceptive use and risk of gestational trophoblastic tumors.

Journal of the National Cancer Institute·1999

Gestational trophoblastic tumors are highly treatable, with over 90% cure rates due to chemotherapy sensitivity and effective monitoring. Prognostic factors guide treatment selection for both low- and high-risk patients.

Area of Science:

  • Gynecology
  • Oncology
  • Pathology

Background:

  • Gestational trophoblastic tumors (GTTs) encompass invasive mole, choriocarcinoma, and placental-site trophoblastic tumor.
  • Current treatment strategies have achieved a remarkable overall cure rate exceeding 90% for these malignancies.

Purpose of the Study:

  • To review the key factors contributing to the high success rates in treating GTTs.
  • To outline treatment approaches based on risk stratification and prognostic indicators.

Main Methods:

  • Analysis of treatment outcomes for GTTs based on chemotherapy sensitivity, tumor marker monitoring (human chorionic gonadotropin), and prognostic factors.
  • Categorization of patients into low- and high-risk groups for tailored therapeutic selection.

Related Experiment Videos

Main Results:

  • Single-agent chemotherapy (methotrexate or Actinomycin-D) is highly effective for nonmetastatic and low-risk metastatic disease.
  • Combination chemotherapy, potentially with radiotherapy and surgery, achieves 80-90% cure rates in high-risk metastatic cases.
  • Key prognostic factors influencing treatment response include diagnosis, metastatic sites, number of metastases, prior chemotherapy failure, and WHO score.

Conclusions:

  • Gestational trophoblastic tumors demonstrate excellent response to chemotherapy.
  • Effective risk stratification and targeted treatment selection are crucial for optimizing cure rates in GTT management.